Advanced Malignant Tumors
33
10
14
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 33 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (33)
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
SG2918 For Advanced Malignant Tumors
A Study of AK112 in Advanced Malignant Tumors
A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumors
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors
A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors
A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
JSKN033 in Chinese Subjects with Advanced Malignant Tumors
AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
A Study of AK130 in Patients With Advanced Malignant Tumors
Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors